The US botox marketing playbook — everything a serious injectable practice needs to run the play at $50K/mo and beyond
This is the complete tactical playbook Ichelon Consulting US runs for US injectable practices. Not a listicle, not a positioning statement, not a case study — the actual step-by-step build: how to segment the buyer, how to write ad copy that passes Meta Personal Attributes review on the first submission, how to wire offline-conversion attribution back to booked visits, how to layer Alle and Aspire loyalty on top of an internal membership, and how to design a 12-16 week rebooking cadence that compounds. Read it end to end. Ship the play. Or send it to us to run.
- A US botox marketing program does not scale on creative alone — it scales on the four things a generic agency almost never gets right at the same time: preventative-vs-corrective buyer segmentation, Meta Personal Attributes-safe creative, offline-conversion attribution back to booked visits, and a rebooking cadence that runs the 12-16 week neuromodulator rhythm.
- Stabilised CPQL for US botox campaigns runs $40 to $120 per consult-booked or first-visit-booked lead. Manhattan, LA West Side, Miami Beach, Highland Park Dallas, San Francisco Marina at the top. Suburban submarkets at the low end. First eight weeks run 30-80% above stabilised while the algorithm learns.
- Compliance is a specification the creative is written to and the analytics is instrumented against — not a legal review that happens after launch. HIPAA + FDA + state medical board + Meta Personal Attributes + TCPA + FTC + FTC endorsement + CAN-SPAM + ADA layered into the ad-review flow.
- Retainers $2,500 to $8,000/month scoped per practice against provider count, location count, and target monthly booked-consult volume. Media spend passes through and is scoped separately.
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
Why most US botox marketing programs plateau around $20K/mo and never break through
Every US injectable practice we scope has already run at least one marketing program that plateaued. The pattern is consistent: the first three months feel promising, the algorithm produces a run of cheap leads, the practice signs on for a second and third quarter, and then CPQL climbs, creative fatigues, the rebooking cadence never actually shipped, and the whole program flattens somewhere between $12K and $22K of monthly media spend. The medical director asks for a report, gets a screenshot of a Meta dashboard, and quietly starts calling around for a replacement agency.
The plateau is not a spend problem. It is four separate failures compounding at the same time. Fixing one at a time produces incremental gains that regress. Fixing all four at once resets the ceiling.
Failure one: buyer segmentation collapsed into a single funnel. Preventative-buyer botox (women and men 26-38 buying maintenance for a face that has not yet developed static lines) and corrective-buyer botox (women and men 38-58 buying sustained cadence for a face that already shows static lines) are two different products with two different offers, two different landing pages, and two different creative libraries. An agency running one funnel for both is optimising the algorithm toward the mid-audience — which converts worse than either segment does when it is targeted correctly.
Failure two: Meta Personal Attributes drift. The Meta Personal Attributes policy prohibits ad copy that asserts or implies knowledge of the viewers appearance, age, weight, condition, or perceived flaw. Every third aesthetic ad in circulation violates it. Most survive review by luck and get flagged later, which quietly demotes the account in the auction. The scoped answer is a hook-writing discipline that stays anchored in offer, provider, city, appointment availability, package structure, or educational framing. Never a claim about the viewers face or body.
Failure three: attribution stopped at the form fill. A form fill that never books is a leak, not a win. The algorithm cannot optimise toward booked visits if the booked-visit signal is not being uploaded from the practice management system back into the ad platforms weekly. Nine out of ten programs we scope have never uploaded a single offline conversion. The algorithm is optimising toward form-fill volume, which is why CPQL looks fine in month two and CAC is atrocious by month four.
Failure four: no rebooking cadence. Neuromodulator retreatment runs 12-16 weeks. If the second, third, and fourth appointments are not being pulled forward by an educational nurture, a rebooking prompt, and a same-week appointment offer wired into the CRM, the lifetime value collapses at the point where a compliant, disciplined program would be compounding. Every retained patient is worth 6-10x their acquisition cost. Losing them to inertia is the most expensive failure in the whole playbook.
The playbook below fixes all four in the same build. Each section is self-contained and shippable. Read it end to end, ship it, or send it to us to ship on your behalf.
Preventative buyer versus corrective buyer — the segmentation everything else depends on
Before a single ad is written, the buyer segmentation has to be decided and the two segments have to be worked as separate funnels. Everything downstream — landing page, creative, offer, follow-up cadence, membership pitch — is scoped against which segment the ad is speaking to.
The preventative buyer
Preventative-buyer botox is the growth engine of the modern injectable practice. The demographic is women and men 26-38 (skew female, but the male share has doubled since 2020), typically single-syringe or micro-dose, treatment cadence in the 4-6 month band, purchase decision driven by peer signal and educational content rather than by a visible concern. Average first-visit ticket $350-$650. Twelve-month LTV $1,400-$2,800 if the rebooking rhythm actually runs. Membership attach rate 25-45% inside the first 90 days.
Preventative-buyer creative anchors in education, provider trust markers, and low-commitment consult framing. First-syringe offers, micro-dose framing, and "start smaller than you think" positioning outperform aggressive package pitches at this stage. Landing pages carry a provider photo, a brief provider bio, an on-site education library, and a booking calendar with an obviously low-friction consult slot. Ad copy stays inside the preventative frame — no reference to "erasing" lines, no before/after positioning, no comparison against the viewers face.
The corrective buyer
Corrective-buyer botox is the profitability engine. The demographic is women and men 38-58 (skew female, higher-ticket male segment 42-56), typically 30-60 units per treatment, cadence 12-16 weeks, purchase decision driven by cumulative-outcome framing and combination-treatment framing (botox + filler, botox + laser, botox + skin resurfacing). Average first-visit ticket $650-$1,400. Twelve-month LTV $3,200-$7,500 if the combination pitch lands. Membership attach rate 45-70% inside the first 60 days.
Corrective-buyer creative anchors in combination-treatment framing, provider credentials, and package pricing that signals the practice runs sustained cadences (not one-off treatments). Landing pages carry combination-treatment education, package tiers with clear cadence assumptions, financing information (CareCredit, Alphaeon, PatientFi, Cherry — see the injectable consultation conversion playbook for full financing discipline), and a same-week booking calendar. Ad copy stays inside cumulative-outcome framing — no reference to individual physical characteristics, no before/after that features the viewer.
Why running one funnel for both segments quietly destroys unit economics
An agency that runs one funnel forces the algorithm to optimise toward the middle audience — someone 32-44 whose response signal is a mix of both segments. That mid-audience converts worse than either segment does when it is targeted correctly, and the algorithm learns increasingly generic patterns over time. The result is a CPQL that looks acceptable in month two and drifts upward through months four, five, and six as creative fatigue accelerates. The fix is two funnels running side by side with their own creative rotations, their own landing pages, their own follow-up cadences, and their own CAC:LTV report lines.
The complete tactical build — every step marked, every output specified
Follow the steps in order. Steps one through three build the foundation. Steps four through six ship the paid program. Steps seven and eight compound the retained cohort. Skipping steps to launch faster is the failure pattern this playbook is designed to prevent.
1Positioning audit — segment before spending
Deliverable: a written positioning brief that names the two buyer segments (preventative and corrective) with demographic bounds, expected first-visit ticket, 12-month LTV assumption, expected membership attach rate, and the creative and landing-page implications for each. No ad account gets built until the positioning brief is signed off by the medical director. Estimated build time: 5-7 business days. Owner: strategy lead + medical director.
2Compliance envelope build — the six layers wired in before launch
Deliverable: a compliance runbook covering (a) HIPAA on tracking pixels, CAPI, session recording, chat widgets, and any embed that touches PHI; (b) FDA on-label injectable claim boundaries with a specific vocabulary of approved and prohibited language; (c) the applicable state medical board rules on before/after, testimonials, superiority claims, and provider identification; (d) Meta Personal Attributes policy applied to every ad hook with sample-passable and sample-failable rewrites; (e) TCPA-safe lead-form consent language plus SMS opt-in and revocation flows against the FCC 2024 rules; (f) FTC endorsement guides for influencer and review-incentive programs. The runbook lives inside the ad-review flow, not in a legal drawer. Estimated build time: 10-14 business days. Owner: performance lead + compliance reviewer.
3Landing page architecture — two variants, tested
Deliverable: two landing pages built to the segmentation from step one. Preventative-buyer LP anchored on education, provider bio, an on-site education library, a low-friction consult calendar. Corrective-buyer LP anchored on combination-treatment framing, package tiers, financing information, a same-week booking calendar. Both pages HIPAA-scoped (no PHI in URLs, no PHI in query parameters, no PHI in event names), Core Web Vitals green (LCP under 2.5s, INP under 200ms, CLS under 0.1), ADA-compliant (WCAG 2.2 AA), and equipped with the practices booking widget hard-wired into the calendar. Estimated build time: 8-12 business days. Owner: web lead + practice manager.
4Creative library — 20-40 hooks per month, all Personal Attributes-safe
Deliverable: a creative library of 20-40 fresh creatives per month at $50K+/mo spend levels (12-20 at lower spend). Every hook rewritten against the Meta Personal Attributes policy before Ad Library submission. Every image scoped against the state medical board rules on before/after and testimonials. Every video scoped against the TikTok aesthetic-services policy (if TikTok is in the channel mix). Rotation cadence tied to Ad Library monitoring signal — creatives that fatigue past 45 days get retired before CPQL climbs. Estimated build time: continuous. Owner: creative lead + performance lead.
5Ad Library monitoring on 8-15 scoped competitor practices
Deliverable: a weekly Ad Library review covering 8-15 scoped competitor practices in the metro. Track creative launches (new hook angles worth testing), creative fatigue (competitor ads running past 60 days signal the market is under-exploiting an angle), offer changes (a $99 first-syringe rollout is a market signal that the competitors CAC math has shifted), and disclaimer patterns (how the market is threading FDA and state board rules). Reallocate a share of the monthly creative production budget to the angles the local market is under-exploiting. Estimated build time: 3-4 hours per week ongoing. Owner: performance lead.
6Attribution stack — GA4 PHI-safe + offline uploads + BAA call tracking
Deliverable: GA4 property configured with PHI-safe event names, service-name query parameters stripped at the tag manager level, deep-link URLs wrapped in pixel-safe redirects. Offline conversion uploads from the practice management system into Google Ads and Meta on booked-visit and cash-collected triggers, running weekly at minimum. Call tracking on a BAA-covered platform with transcript scoring for qualification signal and outcome, mapped back to source campaign and creative. Output: a weekly CAC:LTV report per campaign, per creative, per submarket that the medical director actually reads. Estimated build time: 12-16 business days. Owner: analytics lead + practice manager.
7Loyalty and membership integration — Alle, Aspire, internal
Deliverable: booking flow wired to enrol every consult-to-treatment conversion in the correct manufacturer loyalty program at the point of first product administration. Alle (Allergan Aesthetics — Botox, Juvederm, Kybella, Latisse) for Allergan patients. Aspire (Galderma — Dysport, Restylane, Sculptra) for Galderma patients. Practices that carry both product families run both enrolments in parallel. On top of manufacturer loyalty, an internal membership program that stacks its benefits on top of the manufacturer rewards — practice-specific rewards, event pricing, product-launch access, provider-authored educational content. Estimated build time: 6-10 business days. Owner: practice manager + membership lead.
8Retention and rebooking cadence — the 12-16 week rhythm
Deliverable: a per-patient rebooking cadence wired into the CRM covering an educational nurture touchpoint at week 6, a rebooking prompt at week 10, a same-week appointment offer at week 12, a reactivation prompt at week 14, and a lapsed-patient offer at week 18. Every message TCPA-compliant with an explicit opt-in on the lead form and a one-click revocation flow. Every email inside the CAN-SPAM envelope. Every touchpoint tied to a booking outcome the analytics stack can measure. Reactivation cohort worked separately with a different offer and a different creative rotation. Estimated build time: 10-14 business days. Owner: CRM lead + practice manager. Steady-state contribution to LTV: 40-60% of 12-month revenue per patient.
Every regulator, every platform, every rule the botox program runs inside
Compliance is not a legal review that happens after launch. It is the specification the creative is written to and the analytics is instrumented against. Every layer below is enforced at the ad-review level, re-scoped whenever a regulator or platform issues updated guidance, and audited weekly against the live account.
HIPAA and the OCR tracking-tech guidance
The 2022 OCR Bulletin and the March 2024 update treat identifiable event data tied to condition or provider information as PHI when it is sent to a third-party analytics or ad platform. For an injectable practice, a URL like /services/botox-forehead-lines or /services/kybella-double-chin combined with a Meta CAPI event carrying an IP address, hashed email, or cookie ID is a PHI transmission unless the third party is under a BAA. Google, Meta, and TikTok do not sign BAAs on standard ad infrastructure. The scope answer is a PHI scrub across GA4, Google Ads enhanced conversions, Meta CAPI, TikTok Events API, session-recording tools, chat widgets, and any HIPAA-exposing embed on the practice website.
FDA on-label injectable claims
Every FDA-approved injectable carries an approved on-label indication. Botox is approved for glabellar lines, crow's feet, and forehead lines (among clinical indications). Dysport is approved for glabellar lines. Xeomin is approved for glabellar lines. Filler indications vary product-by-product. Marketing claims that stay inside the approved indication are defensible. Marketing claims that reach past the approved indication into off-label education inside paid ad copy risk both FDA scrutiny and platform disapproval. The safer path is on-label ad copy, on-site educational content the practice hosts under its own clinical labelling, and in-consult provider-led education inside a documented consent flow.
State medical board rules on before/after, testimonials, superiority claims
Every US state medical board publishes rules that shape aesthetic advertising: written patient consent for images and testimonials, disclosure of atypical results, disclosure of compensation for endorsements, images that reasonably represent actual outcomes, prohibitions on unverifiable superiority framing ("top-rated", "leading", "best"). Texas Rule 165.5 and 165.1, California BPC 651, Florida Rule 64B8-11.001, New York Education Law 6530 all vary in specifics. The scope answer is a per-asset audit trail linking every image and testimonial in circulation to signed consent, disclosure state, and the physician on record. A missing consent removes the asset from rotation.
Meta Personal Attributes policy for aesthetic advertising
Meta's Personal Attributes policy prohibits ad copy that asserts or implies knowledge of the viewer's personal characteristics — physical appearance, age, weight, medical condition, and beauty concerns. Every third aesthetic ad in circulation violates it and either gets rejected on submission or (worse) gets flagged post-launch, which demotes the account in the auction. Every hook is rewritten against the policy before Ad Library scan. Sample-passable hooks: "Preston Hollow tox packages, Tuesday appointments available with our nurse injector." Sample-failable hooks: "Are you unhappy with your forehead lines?"
TCPA and CAN-SPAM on lead-form nurture
Lead-form language, appointment-reminder SMS, patient-education drip, and reactivation outreach all scoped against the TCPA rule set including the FCC's 2024 revocation-of-consent updates. Statutory damages of $500 to $1,500 per violating message make this the highest-cost compliance error a US injectable practice can make. Explicit opt-in language on the lead form. One-click revocation flow on every SMS. Email drip inside the CAN-SPAM envelope with a functional unsubscribe on every send.
FTC endorsement guides on influencers and reviews
Every influencer collaboration, staff-referred patient story, or incentivised Google review triggers the FTC Endorsement Guides. Material connection disclosure, honest depiction of results, truthful representation of the endorser's experience. We do not run influencer or review-incentive programs without a compliant disclosure structure baked into the campaign contract.
TikTok aesthetic-services advertising policy
TikTok restricts before/after photography, restricts language on injectables and surgical procedures, requires a landing page inside their scope. TikTok is a practice-brand and awareness channel for US injectable practices, not an injectable-procedure conversion channel. Scope reflects that — TikTok seeds Search and Meta with brand demand rather than closing directly.
What we found when we studied 555 US med spas on Google
Patients praise the care almost without exception. The one area where complaints outnumber praise is booking and communication, and that is where most med spas can win.
Full study · 555 US med spas across 20 metros · roughly ±4% nationally · review velocity and themes from a 115-spa subsample · verified against raw data.
Alle, Aspire, and internal membership — the three-layer retention stack
A US injectable practice that runs manufacturer loyalty in parallel with an internal membership program creates a retention layer no single-channel program can match. Every consult-to-treatment conversion generates three separate retention hooks — the manufacturer program pulls the patient back for the same product family, the internal membership pulls the patient back for practice-specific benefits, and the CRM cadence pulls the patient back on the 12-16 week rhythm regardless of channel.
Alle (Allergan Aesthetics)
Alle covers Botox, Juvederm, Kybella, Latisse, SkinMedica, CoolSculpting, and the wider Allergan Aesthetics portfolio. Patients earn points on qualifying treatments and redeem for savings on subsequent Allergan Aesthetics products. For practices that carry the Allergan family, wire enrolment into the booking flow at the point of first product administration. The patient walks out enrolled, points already accruing, redemption cadence already primed for the next visit.
Aspire (Galderma)
Aspire Rewards covers Dysport, Restylane, Sculptra, Alastin, and the Galderma aesthetics portfolio. Similar mechanic: patients earn on qualifying treatments and redeem on subsequent Galderma products. For dual-family practices, run enrolment in both programs in parallel — the patient family attached to the product they were treated with, not force-fitted to one program or the other.
Internal membership on top of manufacturer loyalty
Manufacturer loyalty locks the patient to the product family. Internal membership locks the patient to the practice. The stack runs both simultaneously — the manufacturer program gives the patient a reason to buy the same brand, the internal membership gives the patient a reason to buy at this practice. Internal membership benefits usually cover practice-specific rewards, event pricing, product-launch access, provider-authored educational content, and a dedicated concierge line for booking. Membership pricing tiers, retention benchmarks, and stack economics are covered in the medspa membership marketing playbook.
Membership economics versus single-treatment economics — which one to lead with
The question is not "membership or single-treatment." The question is which one leads the acquisition offer and which one carries the retention cohort. A properly scoped program runs both, layered.
Single-treatment as the acquisition offer
Single-treatment offers acquire faster because the friction is lower. A "$99 first-syringe consult" or "package of three at member pricing" or "free consult, same week" gets more people through the door than a "join our $199/month membership" first-visit pitch. The role of single-treatment marketing is to fill the top of the funnel with qualified consults. First-visit ticket $350-$1,400 depending on segment and product mix. CAC $80-$350 depending on submarket and creative maturity.
Membership as the retention layer
Membership captures the second, third, and fourth visits. In-consult membership pitch on visit one converts 25-45% of preventative-segment patients and 45-70% of corrective-segment patients. Retained membership cohort produces a 12-month LTV of $1,400-$7,500 depending on segment, product mix, and cadence adherence. Churn benchmarks 8-14% annual for well-run programs, 22-35% for programs without a retention layer wired into the CRM.
The stack in aggregate
A serious US injectable practice running the playbook end to end generates 60-70% of 12-month revenue from the retained membership cohort and 30-40% from single-treatment acquisition. Programs that flip the ratio (60%+ from single-treatment, 30%- from retention) are burning acquisition dollars to fill a leaky funnel. The retention build in step eight is where the compounding lives.
US botox CPQL benchmarks by metro tier and buyer segment
Numbers below are stabilised US benchmarks after a properly scoped account has been running for 8-12 weeks. Tier-1 metros with the hottest aesthetic auctions run at the top of the range. Suburban submarkets and Tier-3 metros run at the low end. First-eight-weeks CPQL runs 30-80% above stabilised while the algorithm learns the offline-conversion signal.
| Segment / Metro tier | Qualified lead type | CPQL range |
|---|---|---|
| Preventative buyer · Tier-1 metro (NYC, LA, SF, Miami) | Consult-booked | $65 – $120 |
| Preventative buyer · Tier-2 metro (Dallas, Houston, Atlanta, Chicago) | Consult-booked | $45 – $85 |
| Preventative buyer · Tier-3 metro / suburban | Consult-booked | $40 – $65 |
| Corrective buyer · Tier-1 metro | Consult-booked | $75 – $140 |
| Corrective buyer · Tier-2 metro | Consult-booked | $55 – $100 |
| Corrective buyer · Tier-3 metro / suburban | Consult-booked | $45 – $75 |
| Membership-lead ad · any tier | Membership signup | $120 – $260 |
| Reactivation ad · lapsed patient | Rebooking | $18 – $45 |
The important number is CAC:LTV, not CPQL. A $90 preventative CPQL at a 55% close rate and a $520 first-visit ticket that ascends to a $2,200 12-month LTV is a 1:13 ratio — excellent. A $70 corrective CPQL at a 40% close rate and a $1,100 first-visit ticket that ascends to a $6,500 12-month LTV is a 1:37 ratio — outstanding. We report CAC:LTV per campaign, per creative, per submarket. Not CPQL alone.
Retainer scope for US botox marketing programs
Retainers custom-scoped per practice — $2,500 to $8,000 per month against provider count, location count, target monthly booked-consult volume, and the depth of the compliance envelope required. Media spend passes through and is scoped separately. No performance bonuses or CPA-based fees that push the account toward loose qualification — the incentive alignment sits inside the retainer plus a clean weekly CAC:LTV report.
- Solo injector or single-provider aesthetic practice — $2,500 to $4,500/month. One or two primary paid channels, single landing page pair (preventative + corrective), offline-conversion attribution, monthly reporting, quarterly strategy review. Media pass-through typically $6,000 to $18,000/month.
- Two-to-three location injector group — $4,500 to $6,500/month. Full paid stack (Google + Meta + LSA + selective YouTube), Ad Library monitoring, Alle + Aspire integration, internal membership build, weekly CPQL and CAC:LTV reporting. Media pass-through typically $18,000 to $45,000/month.
- Multi-location aesthetic platform or PE-backed injector group — $6,500 to $8,000+/month. Full paid stack, per-location P&L attribution, per-provider content and paid-social scoping, CRM integration, monthly executive review. Media pass-through typically $45,000 to $250,000+/month.
US botox marketing playbook — the questions serious practices ask
What is a realistic CPQL for a US botox marketing program?
Stabilised CPQL for US botox and neuromodulator campaigns runs $40 to $120 per consult-booked or first-visit-booked lead across most metros. Tier-1 metros with hotter aesthetic auctions (Manhattan, LA West Side, Miami Beach, Highland Park Dallas, San Francisco Marina) run at the top of the range. Tier-2 and suburban submarkets run at the low end. First-eight-weeks CPQL runs 30-80% above the stabilised range while the algorithm learns the offline-conversion signal, which is why any evaluation of the program before week 10 is measuring the wrong data.
What Meta ad copy passes Personal Attributes review for injectables?
Copy passes when it stays anchored in offer, provider, city, appointment availability, package structure, or educational framing — and avoids any claim that references the viewers appearance, age, weight, condition, or perceived flaw. "Are you unhappy with your forehead lines?" fails. "Highland Park tox packages, Tuesday appointments available with our nurse injector" passes. "Sagging jawline? Our Kybella program can help" fails. "Kybella program by our board-certified physician, packages of three at member pricing" passes. Every hook is rewritten against the policy before Ad Library scan.
Should a botox practice run membership or single-treatment marketing?
Both, layered. Single-treatment marketing acquires the first visit; membership marketing captures the second, third, and fourth. Practices that market only single-treatment burn 30-45% of the acquisition economics on rebooking friction. Practices that market only membership shrink the top-of-funnel pool. The scoped answer is single-treatment as the acquisition offer, an in-consult membership pitch on visit one that converts 25-70% depending on segment, and membership-holder marketing (upsell, cross-sell, referral) on the retained cohort.
How do Alle and Aspire loyalty programs fit into practice marketing?
Alle (Allergan Aesthetics — Botox, Juvederm, Kybella, Latisse) and Aspire (Galderma — Dysport, Restylane, Sculptra) are manufacturer loyalty programs that give the patient a persistent reason to return to the same practice for the same brand. Wire enrolment into the booking flow so every consult-to-treatment conversion enrols the patient automatically at the point of first product administration. Market membership benefits inside the loyalty ecosystem so the manufacturer program becomes a retention layer on top of the practices own membership.
How do we scale botox ad spend past $50,000 per month without collapsing CPQL?
Three levers. First, geographic expansion into adjacent submarkets with fresh auction pricing rather than doubling spend in a saturated core zip code. Second, creative volume — a fatiguing creative library is the fastest way to blow up CPQL at scale, and $50K+ programs need 20-40 fresh creatives per month scoped against Meta Personal Attributes. Third, offer diversification — layer preventative-buyer and corrective-buyer landing pages, add package tiers, add a membership hook — so the top-of-funnel pool widens rather than deepens.
What is the retention and rebooking cadence for a botox patient?
Neuromodulator retreatment typically runs 12-16 weeks depending on product, dosage, and patient physiology. The rebooking rhythm designs against that: an educational nurture touchpoint at week 6, a rebooking prompt at week 10, a same-week appointment offer at week 12, a reactivation prompt at week 14, and a lapsed-patient offer at week 18 if the patient has not rebooked. Every message TCPA-compliant, every touchpoint tied to a booking outcome, every campaign attributed back to a consult or a treatment.
Can off-label injectable education be run in paid ads?
FDA regulates on-label indication claims; off-label education is a compliance minefield in paid ad copy and platform ad review both. The safer path is on-site clinical education (a properly labelled patient-education library the practice hosts), in-consult provider-led education inside a documented consent flow, and paid ad copy that stays inside on-label indication language. Off-label claims made in paid ad copy risk both FDA scrutiny and platform disapproval. When in doubt, keep off-label education inside the exam room and inside a documented consent flow.
How is Ad Library monitoring different from generic competitor tracking?
Meta Ad Library shows every ad any competing practice is running right now — creative, copy, offer, disclaimer, page linked. Generic competitor tracking watches organic content and public campaigns. Ad Library monitoring reveals paid creative fatigue signals (an ad running for 60+ days without rotation is fatiguing), offer changes (a competitor rolling out a $99 first-syringe offer is a market signal that the local CAC math has shifted), and disclaimer patterns (how competitors are threading FDA and state board rules). Systematised into a weekly review, it is the single fastest way to price the local auction.
Scope your US botox marketing program
Book a 30-minute scoping call with the Leadership Team, email Santosh (Dallas HQ) directly, or WhatsApp us. Central Time hours, same-day response where we can.
Adjacent US aesthetic marketing playbooks
Healthcare brands ICG
has worked with.
A representative slice of the 150+ healthcare brands ICG has delivered for across India. Full client list available under NDA during a Brand and Growth Diagnostic.
